HomeHeadlinesMerck's (MRK) Ifinatamab deruxtecan in adults with extensive-stage small cell lung cancer has been accepted for FDA priority reviewAPRIL 13, 2026 AT 11:00 AMMerck's (MRK) Ifinatamab deruxtecan in adults with extensive-stage small cell lung cancer has been accepted for FDA priority reviewByNewsquawk StaffImportanceLevel 1#GERMANY#EUROPE#MERCK & CO INC#MRK.US#MERCK KGAA#FDA#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DAX 40 INDEX#MRK#US EQUITIES
APRIL 13, 2026 AT 11:00 AMMerck's (MRK) Ifinatamab deruxtecan in adults with extensive-stage small cell lung cancer has been accepted for FDA priority reviewByNewsquawk StaffImportanceLevel 1#GERMANY#EUROPE#MERCK & CO INC#MRK.US#MERCK KGAA#FDA#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DAX 40 INDEX#MRK#US EQUITIES
